个人简介
北航“医工百人”特聘研究员，北航生物医学工程高精尖创新中心研究员，博士生导师。2008年获得清华大学生物学博士学位。2009年进入加州大学圣迭戈分校（UCSD）肿瘤中心从事肿瘤转化医学研究。2018年入职北京航空航天大学医工交叉创新研究院。迄今在包括Cell Stem Cell、JCI、Leukemia、Blood、PNAS等国际权威期刊发表多篇论文，被引用700余次。负责研发的人源化抗ROR1抗体（Cirmtuzumab）进入临床试验研究。
开发新型癌症治疗策略是我们的使命。 凭借生物学，医学，化学和工程等多学科交叉，我们致力于：（1）研发单克隆抗体药物；（2）开发新型嵌合抗原受体T细胞免疫疗法；（3）鉴定临床老药的新用途；（4）开发联合用药治疗。
发表文章：
1. Liu, Z., Liu, J., Zhang, T., Shi, M., Chen, X., Chen, Y., & Yu, J. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Pharmacol Res. 2020; 151:104512.
2. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2017;31(6):1333-9.
3. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, et al. Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017.
4. Yu J, Chen L, Cui B, Widhopf GF, 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016;126(2):585-98.
5. Lu D, Choi MY, Yu J (Co-first author), Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(32):13253-7.
6. Yu J, Zhang L, Chen A, Xiang G, Wang Y, Wu J, et al. Identification of the gene transcription and apoptosis mediated by TGF-beta-Smad2/3-Smad4 signaling. J Cell Physiol. 2008;215(2):422-33.
7. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, 2nd, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-kappaB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134(13):1084-1094.
8. Hasan MK, Yu J, Widhopf GF, 2nd, Rassenti LZ, Chen L, Shen Z, et al. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018.
9. Choi MY, Widhopf GF, 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018;22(6):951-9 e3.
10. Hasan MK, Yu J, Chen L, Cui B, Widhopf Ii GF, Rassenti L, et al. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2017.
11. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, 2nd, Yu J, et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016;128(25):2931-40.
12. Chu D, Zhao Q, Yu J, Zhang F, Zhang H, Wang Z. Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy. Adv Healthc Mater. 2016;5(9):1088-93.
13. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546-54.
14. Chen A, Yu J, Zhang L, Sun Y, Zhang Y, Guo H, et al. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. Biotechnol Lett. 2009;31(4):487-94.
15. Chen A, Luo M, Yuan G, Yu J, Deng T, Zhang L, et al. Complementary analysis of microRNA and mRNA expression during phorbol 12-myristate 13-acetate (TPA)-induced differentiation of HL-60 cells. Biotechnol Lett. 2008;30(12):2045-52.
16. Li DY, Ji XS, Yu J, Chen MJ, Yuan ZY. PCR Based Cloning and Sequence Analysis of the Pichia pastoris Cystathionine beta-Synthase Gene. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2001;33(6):600-6.

教育经历

 清华大学  | 生物医学工程  | 博士学位   | 博士研究生毕业



 吉林大学  | Biology  | Master's Degree   | 硕士研究生毕业



 吉林大学  | Biology  | Bachelor's Degree   | 大学本科毕业



工作经历

UCSD Moores Cancer Center|项目研究员



研究方向
基于噬菌体展示技术的单克隆抗体（包括传统抗体和纳米抗体）筛选，研发新型抗肿瘤单克隆抗体药物和抗体药物偶联物（ADC）靶向疗法，以及嵌合抗原受体T细胞（CAR-T）免疫疗法。
基于基因组学、转录组学、蛋白质组学、代谢组学等多组学技术的抗肿瘤药物药理、药效和毒理研究，开发老药新用和联合用药的肿瘤精准治疗新策略，借以克服抗肿瘤药物的肿瘤耐药性并降低药物毒副作用。

---

基本信息
姓名：于健
学位：博士学位
职称：研究员
单位：北京航空航天大学
个人简介
北航“医工百人”特聘研究员，北航生物医学工程高精尖创新中心研究员，博士生导师。2008年获得清华大学生物学博士学位。2009年进入加州大学圣迭戈分校（UCSD）肿瘤中心从事肿瘤转化医学研究。2018年入职北京航空航天大学医工交叉创新研究院。迄今在包括Cell Stem Cell、JCI、Leukemia、Blood、PNAS等国际权威期刊发表多篇论文，被引用700余次。负责研发的人源化抗ROR1抗体（Cirmtuzumab）进入临床试验研究。
开发新型癌症治疗策略是我们的使命。 凭借生物学，医学，化学和工程等多学科交叉，我们致力于：（1）研发单克隆抗体药物；（2）开发新型嵌合抗原受体T细胞免疫疗法；（3）鉴定临床老药的新用途；（4）开发联合用药治疗。
发表文章：
1. Liu, Z., Liu, J., Zhang, T., Shi, M., Chen, X., Chen, Y., & Yu, J. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Pharmacol Res. 2020; 151:104512.
2. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2017;31(6):1333-9.
3. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, et al. Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017.
4. Yu J, Chen L, Cui B, Widhopf GF, 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016;126(2):585-98.
5. Lu D, Choi MY, Yu J (Co-first author), Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(32):13253-7.
6. Yu J, Zhang L, Chen A, Xiang G, Wang Y, Wu J, et al. Identification of the gene transcription and apoptosis mediated by TGF-beta-Smad2/3-Smad4 signaling. J Cell Physiol. 2008;215(2):422-33.
7. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, 2nd, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-kappaB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134(13):1084-1094.
8. Hasan MK, Yu J, Widhopf GF, 2nd, Rassenti LZ, Chen L, Shen Z, et al. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018.
9. Choi MY, Widhopf GF, 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018;22(6):951-9 e3.
10. Hasan MK, Yu J, Chen L, Cui B, Widhopf Ii GF, Rassenti L, et al. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2017.
11. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, 2nd, Yu J, et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016;128(25):2931-40.
12. Chu D, Zhao Q, Yu J, Zhang F, Zhang H, Wang Z. Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy. Adv Healthc Mater. 2016;5(9):1088-93.
13. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546-54.
14. Chen A, Yu J, Zhang L, Sun Y, Zhang Y, Guo H, et al. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. Biotechnol Lett. 2009;31(4):487-94.
15. Chen A, Luo M, Yuan G, Yu J, Deng T, Zhang L, et al. Complementary analysis of microRNA and mRNA expression during phorbol 12-myristate 13-acetate (TPA)-induced differentiation of HL-60 cells. Biotechnol Lett. 2008;30(12):2045-52.
16. Li DY, Ji XS, Yu J, Chen MJ, Yuan ZY. PCR Based Cloning and Sequence Analysis of the Pichia pastoris Cystathionine beta-Synthase Gene. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2001;33(6):600-6.
研究领域
当前位置 : 中文主页 >> 研究领域

---

基本信息
姓名：于健

学位：博士学位
职称：研究员
单位：北京航空航天大学
个人简介
北航“医工百人”特聘研究员，北航生物医学工程高精尖创新中心研究员，博士生导师。2008年获得清华大学生物学博士学位。2009年进入加州大学圣迭戈分校（UCSD）肿瘤中心从事肿瘤转化医学研究。2018年入职北京航空航天大学医工交叉创新研究院。迄今在包括Cell Stem Cell、JCI、Leukemia、Blood、PNAS等国际权威期刊发表多篇论文，被引用700余次。负责研发的人源化抗ROR1抗体（Cirmtuzumab）进入临床试验研究。
开发新型癌症治疗策略是我们的使命。 凭借生物学，医学，化学和工程等多学科交叉，我们致力于：（1）研发单克隆抗体药物；（2）开发新型嵌合抗原受体T细胞免疫疗法；（3）鉴定临床老药的新用途；（4）开发联合用药治疗。
发表文章：
1. Liu, Z., Liu, J., Zhang, T., Shi, M., Chen, X., Chen, Y., & Yu, J. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Pharmacol Res. 2020; 151:104512.
2. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2017;31(6):1333-9.
3. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, et al. Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017.
4. Yu J, Chen L, Cui B, Widhopf GF, 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016;126(2):585-98.
5. Lu D, Choi MY, Yu J (Co-first author), Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(32):13253-7.
6. Yu J, Zhang L, Chen A, Xiang G, Wang Y, Wu J, et al. Identification of the gene transcription and apoptosis mediated by TGF-beta-Smad2/3-Smad4 signaling. J Cell Physiol. 2008;215(2):422-33.
7. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, 2nd, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-kappaB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134(13):1084-1094.
8. Hasan MK, Yu J, Widhopf GF, 2nd, Rassenti LZ, Chen L, Shen Z, et al. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018.
9. Choi MY, Widhopf GF, 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018;22(6):951-9 e3.
10. Hasan MK, Yu J, Chen L, Cui B, Widhopf Ii GF, Rassenti L, et al. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2017.
11. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, 2nd, Yu J, et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016;128(25):2931-40.
12. Chu D, Zhao Q, Yu J, Zhang F, Zhang H, Wang Z. Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy. Adv Healthc Mater. 2016;5(9):1088-93.
13. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546-54.
14. Chen A, Yu J, Zhang L, Sun Y, Zhang Y, Guo H, et al. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. Biotechnol Lett. 2009;31(4):487-94.
15. Chen A, Luo M, Yuan G, Yu J, Deng T, Zhang L, et al. Complementary analysis of microRNA and mRNA expression during phorbol 12-myristate 13-acetate (TPA)-induced differentiation of HL-60 cells. Biotechnol Lett. 2008;30(12):2045-52.
16. Li DY, Ji XS, Yu J, Chen MJ, Yuan ZY. PCR Based Cloning and Sequence Analysis of the Pichia pastoris Cystathionine beta-Synthase Gene. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2001;33(6):600-6.
开授课程
当前位置 : 中文主页 >> 开授课程


共0条0/0

---

基本信息
姓名：于健
学位：博士学位
职称：研究员
单位：北京航空航天大学
个人简介
北航“医工百人”特聘研究员，北航生物医学工程高精尖创新中心研究员，博士生导师。2008年获得清华大学生物学博士学位。2009年进入加州大学圣迭戈分校（UCSD）肿瘤中心从事肿瘤转化医学研究。2018年入职北京航空航天大学医工交叉创新研究院。迄今在包括Cell Stem Cell、JCI、Leukemia、Blood、PNAS等国际权威期刊发表多篇论文，被引用700余次。负责研发的人源化抗ROR1抗体（Cirmtuzumab）进入临床试验研究。
开发新型癌症治疗策略是我们的使命。 凭借生物学，医学，化学和工程等多学科交叉，我们致力于：（1）研发单克隆抗体药物；（2）开发新型嵌合抗原受体T细胞免疫疗法；（3）鉴定临床老药的新用途；（4）开发联合用药治疗。
发表文章：
1. Liu, Z., Liu, J., Zhang, T., Shi, M., Chen, X., Chen, Y., & Yu, J. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Pharmacol Res. 2020; 151:104512.
2. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2017;31(6):1333-9.
3. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, et al. Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017.
4. Yu J, Chen L, Cui B, Widhopf GF, 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016;126(2):585-98.
5. Lu D, Choi MY, Yu J (Co-first author), Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(32):13253-7.
6. Yu J, Zhang L, Chen A, Xiang G, Wang Y, Wu J, et al. Identification of the gene transcription and apoptosis mediated by TGF-beta-Smad2/3-Smad4 signaling. J Cell Physiol. 2008;215(2):422-33.
7. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, 2nd, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-kappaB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134(13):1084-1094.
8. Hasan MK, Yu J, Widhopf GF, 2nd, Rassenti LZ, Chen L, Shen Z, et al. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018.
9. Choi MY, Widhopf GF, 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018;22(6):951-9 e3.
10. Hasan MK, Yu J, Chen L, Cui B, Widhopf Ii GF, Rassenti L, et al. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2017.
11. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, 2nd, Yu J, et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016;128(25):2931-40.
12. Chu D, Zhao Q, Yu J, Zhang F, Zhang H, Wang Z. Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy. Adv Healthc Mater. 2016;5(9):1088-93.
13. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546-54.
14. Chen A, Yu J, Zhang L, Sun Y, Zhang Y, Guo H, et al. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. Biotechnol Lett. 2009;31(4):487-94.
15. Chen A, Luo M, Yuan G, Yu J, Deng T, Zhang L, et al. Complementary analysis of microRNA and mRNA expression during phorbol 12-myristate 13-acetate (TPA)-induced differentiation of HL-60 cells. Biotechnol Lett. 2008;30(12):2045-52.
16. Li DY, Ji XS, Yu J, Chen MJ, Yuan ZY. PCR Based Cloning and Sequence Analysis of the Pichia pastoris Cystathionine beta-Synthase Gene. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2001;33(6):600-6.
科研项目
当前位置 : 中文主页 >> 科研项目


共0条0/0

---

基本信息
姓名：于健
学位：博士学位
职称：研究员
单位：北京航空航天大学
个人简介
北航“医工百人”特聘研究员，北航生物医学工程高精尖创新中心研究员，博士生导师。2008年获得清华大学生物学博士学位。2009年进入加州大学圣迭戈分校（UCSD）肿瘤中心从事肿瘤转化医学研究。2018年入职北京航空航天大学医工交叉创新研究院。迄今在包括Cell Stem Cell、JCI、Leukemia、Blood、PNAS等国际权威期刊发表多篇论文，被引用700余次。负责研发的人源化抗ROR1抗体（Cirmtuzumab）进入临床试验研究。
开发新型癌症治疗策略是我们的使命。 凭借生物学，医学，化学和工程等多学科交叉，我们致力于：（1）研发单克隆抗体药物；（2）开发新型嵌合抗原受体T细胞免疫疗法；（3）鉴定临床老药的新用途；（4）开发联合用药治疗。
发表文章：
1. Liu, Z., Liu, J., Zhang, T., Shi, M., Chen, X., Chen, Y., & Yu, J. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Pharmacol Res. 2020; 151:104512.
2. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2017;31(6):1333-9.
3. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, et al. Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017.
4. Yu J, Chen L, Cui B, Widhopf GF, 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016;126(2):585-98.
5. Lu D, Choi MY, Yu J (Co-first author), Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(32):13253-7.
6. Yu J, Zhang L, Chen A, Xiang G, Wang Y, Wu J, et al. Identification of the gene transcription and apoptosis mediated by TGF-beta-Smad2/3-Smad4 signaling. J Cell Physiol. 2008;215(2):422-33.
7. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, 2nd, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-kappaB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134(13):1084-1094.
8. Hasan MK, Yu J, Widhopf GF, 2nd, Rassenti LZ, Chen L, Shen Z, et al. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018.
9. Choi MY, Widhopf GF, 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018;22(6):951-9 e3.
10. Hasan MK, Yu J, Chen L, Cui B, Widhopf Ii GF, Rassenti L, et al. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2017.
11. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, 2nd, Yu J, et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016;128(25):2931-40.
12. Chu D, Zhao Q, Yu J, Zhang F, Zhang H, Wang Z. Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy. Adv Healthc Mater. 2016;5(9):1088-93.
13. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546-54.
14. Chen A, Yu J, Zhang L, Sun Y, Zhang Y, Guo H, et al. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. Biotechnol Lett. 2009;31(4):487-94.
15. Chen A, Luo M, Yuan G, Yu J, Deng T, Zhang L, et al. Complementary analysis of microRNA and mRNA expression during phorbol 12-myristate 13-acetate (TPA)-induced differentiation of HL-60 cells. Biotechnol Lett. 2008;30(12):2045-52.
16. Li DY, Ji XS, Yu J, Chen MJ, Yuan ZY. PCR Based Cloning and Sequence Analysis of the Pichia pastoris Cystathionine beta-Synthase Gene. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2001;33(6):600-6.
论文
当前位置 : 中文主页 >> 论文


共0条0/0

---

基本信息
姓名：于健
学位：博士学位
职称：研究员
单位：北京航空航天大学
个人简介
北航“医工百人”特聘研究员，北航生物医学工程高精尖创新中心研究员，博士生导师。2008年获得清华大学生物学博士学位。2009年进入加州大学圣迭戈分校（UCSD）肿瘤中心从事肿瘤转化医学研究。2018年入职北京航空航天大学医工交叉创新研究院。迄今在包括Cell Stem Cell、JCI、Leukemia、Blood、PNAS等国际权威期刊发表多篇论文，被引用700余次。负责研发的人源化抗ROR1抗体（Cirmtuzumab）进入临床试验研究。
开发新型癌症治疗策略是我们的使命。 凭借生物学，医学，化学和工程等多学科交叉，我们致力于：（1）研发单克隆抗体药物；（2）开发新型嵌合抗原受体T细胞免疫疗法；（3）鉴定临床老药的新用途；（4）开发联合用药治疗。
发表文章：
1. Liu, Z., Liu, J., Zhang, T., Shi, M., Chen, X., Chen, Y., & Yu, J. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Pharmacol Res. 2020; 151:104512.
2. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2017;31(6):1333-9.
3. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, et al. Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017.
4. Yu J, Chen L, Cui B, Widhopf GF, 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016;126(2):585-98.
5. Lu D, Choi MY, Yu J (Co-first author), Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(32):13253-7.
6. Yu J, Zhang L, Chen A, Xiang G, Wang Y, Wu J, et al. Identification of the gene transcription and apoptosis mediated by TGF-beta-Smad2/3-Smad4 signaling. J Cell Physiol. 2008;215(2):422-33.
7. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, 2nd, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-kappaB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134(13):1084-1094.
8. Hasan MK, Yu J, Widhopf GF, 2nd, Rassenti LZ, Chen L, Shen Z, et al. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018.
9. Choi MY, Widhopf GF, 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018;22(6):951-9 e3.
10. Hasan MK, Yu J, Chen L, Cui B, Widhopf Ii GF, Rassenti L, et al. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2017.
11. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, 2nd, Yu J, et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016;128(25):2931-40.
12. Chu D, Zhao Q, Yu J, Zhang F, Zhang H, Wang Z. Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy. Adv Healthc Mater. 2016;5(9):1088-93.
13. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546-54.
14. Chen A, Yu J, Zhang L, Sun Y, Zhang Y, Guo H, et al. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. Biotechnol Lett. 2009;31(4):487-94.
15. Chen A, Luo M, Yuan G, Yu J, Deng T, Zhang L, et al. Complementary analysis of microRNA and mRNA expression during phorbol 12-myristate 13-acetate (TPA)-induced differentiation of HL-60 cells. Biotechnol Lett. 2008;30(12):2045-52.
16. Li DY, Ji XS, Yu J, Chen MJ, Yuan ZY. PCR Based Cloning and Sequence Analysis of the Pichia pastoris Cystathionine beta-Synthase Gene. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2001;33(6):600-6.
荣誉及奖励
当前位置 : 中文主页 >> 荣誉及奖励


共0条0/0